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Pregnancies in young women with diagnosis and treatment of 
HER2-positive breast cancer
Matteo Lambertini and Giulia Viglietti
Young breast cancer patients who have not yet 
completed their family planning at the time of diagnosis 
may still have pregnancy desire at the completion of 
adequate anticancer treatments and period of follow-up. 
Indeed, young women advocates have recently highlighted 
that pregnancy-related concerns have high priority [1]. 
Despite many physicians remain concerned that pregnancy 
in breast cancer survivors may have a detrimental 
prognostic effect by means of endocrine stimulation [2], 
increasing evidence has become available over the years 
on the safety of conceiving for patients with prior history 
of breast cancer diagnosis and treatment [3, 4]. However, 
there was lack of data on this regard to properly counsel 
young women with newly diagnosed HER2-positive 
breast cancer. In addition, considering both the suboptimal 
use of contraceptive methods among breast cancer patients 
[5] as well as the apparent lack of gonadotoxicity with 
the administration of trastuzumab (and/or lapatinib) [6], 
some physicians may need to counsel young women 
with HER2-positive breast cancer that have become 
accidentally pregnant during anti-HER2 targeted therapy. 
Considering that almost half of breast cancer physicians 
that have recently responded to a recent survey believe 
that first-trimester expsoure to trastuzumab is associated 
with high risk of malformations [2], many women in 
this situation are likely to be counseled about the need to 
terminate their pregnancy.
To investigate the prognostic effect of conceiving 
after diagnosis of HER2-positive early breast cancer and 
in order to provide evidence on the effect of exposure 
to the anti-HER2 agents trastuzumab and/or lapatinib 
on pregnancy outcomes, a recent analysis of all the 
pregnancy events that occurred as part of the NeoAdjuvant 
Lapatinib and/or Trastuzumab Treatment Optimization 
(NeoALTTO; NCT00553358) and the Adjuvant Lapatinib 
and/or Trastuzumab Treatment Optimization (ALTTO; 
NCT00490139) trials has been conducted [7]. Following 
study inclusion, among patients with ≤40 years at the time 
of diagnosis, 7 (7.5%) in the NeoALTTO trial and 85 
(6.1%) in the ALTTO trial had a subsequent pregnancy, 
respectively. To assess the prognostic effect of conceiving 
after prior HER2-positive early breast cancer, the extended 
Cox model with time-varying covariates was used to 
account for guarantee-time bias by comparing disease-
free survival between young patients with or without a 
subsequent pregnancy (this analysis included only women 
enrolled in the ALTTO trial). No significant difference in 
disease-free survival was observed between patients with 
or without a subsequent pregnancy (adjusted hazard ratio, 
1.12; 95% confidence intervals, 0.52-2.42). Importantly, 
this analysis provides for the first time evidence on the 
safety of pregnancy in breast cancer survivors with 
HER2-positive disease and using data from a prospective 
randomized trial. In terms of pregnancy outcomes, out of 
92 patients with at least one pregnancy after randomization 
in the two studies, 12 were unintentionally exposed to 
anti-HER2 therapy during gestation or shortly after its 
termination (exposed group) and 80 conceived following 
the completion of anti-HER2 targeted therapy (i.e. 
unexposed group). Among the 12 patients in the exposed 
group, 7 opted for an induced abortion and 5 decided to 
stop the treatment for continuing their pregnancy: all these 
5 pregnancies resulted in live births with no congenital 
anomalies or pregnancy/delivery complications. Among 
the 80 patients in the unexposed group, 10 (12.5%) opted 
for an induced abortion and 10 (12.5%) had a spontaneous 
abortion; among the 54 (67.5%) patients who successfully 
completed their pregnancy, there were no pregnancy/
delivery complications with the exception of one fetus 
(1.9%) with trisomy 21 (Down syndrome) [7]. 
There are two main messages deriving from 
this analysis. First, these findings reinforce the current 
recommendation that having a pregnancy after prior 
history of breast cancer should not be contraindicated 
after adequate treatment and follow-up [8, 9]. This 
statement appears to be valid in breast cancer survivors 
irrespectively of their tumor biology, including among 
women with HER2-positive disease. Second, although 
targeted therapies should not be actively administered 
during pregnancy as per current guidelines [8, 10], the 
limited data available with short accidental exposure to 
these agents during the first-trimester [11, 12] (including 
the recent findings from the NeoALTTO and ALTTO 
trials) may be partially reassuring about the low risk 
of congenital malformation. Therefore, pregnancy 
termination is probably not justified in this setting [13].
Results from the ongoing MotHER study 
(NCT00833963) collecting prospective information on 
patients exposed to anti-HER2 therapies during pregnancy 
as well as similar analyses from the large adjuvant trials 
that led to the approval of pertuzumab and neratinib in 
the early setting are awaited to provide further evidence 
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in order to improve the counseling of young women with 
newly diagnosed HER2-positive breast cancer facing 
pregnancy-related concerns.
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